key: cord-0715552-hinu974s authors: Sun, Yaping; Dong, Wenjuan; Tian, Lei; Rao, Youliang; Qin, Chao; Jaramillo, Sierra A.; Settles, Erik W.; Ma, Shoubao; Zhang, Jianying; Yu, Kang; Xu, Bo; Yan, Jiazhuo; Ma, Rui; Li, Zhuo; Dadwal, Sanjeet S.; Barker, Bridget M.; Keim, Paul S.; Feng, Pinghui; Caligiuri, Michael A.; Yu, Jianhua title: Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression date: 2021-06-07 journal: bioRxiv DOI: 10.1101/2021.06.07.447286 sha: b2f4b23571dd88a44a78ea8fd47db830c74247b5 doc_id: 715552 cord_uid: hinu974s The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Cancer patients are usually immunocompromised and thus are particularly susceptible to SARS-CoV-2 infection resulting in COVID-19. Although many vaccines against COVID-19 are being preclinically or clinically tested or approved, none have yet been specifically developed for cancer patients or reported as having potential dual functions to prevent COVID-19 and treat cancer. Here, we confirmed that COVID-19 patients with cancer have low levels of antibodies against the spike (S) protein, a viral surface protein mediating the entry of SARS-CoV-2 into host cells, compared with COVID-19 patients without cancer. We developed an oncolytic herpes simplex virus-1 vector-based vaccine named oncolytic virus (OV)-spike. OV-spike induced abundant anti-S protein neutralization antibodies in both tumor-free and tumor-bearing mice, which inhibit infection of VSV-SARS-CoV-2 and wild-type (WT) live SARS-CoV-2 as well as the B.1.1.7 variant in vitro. In the tumor-bearing mice, OV-spike also inhibited tumor growth, leading to better survival in multiple preclinical tumor models than the untreated control. Furthermore, OV-spike induced anti-tumor immune response and SARS-CoV-2-specific T cell response without causing serious adverse events. Thus, OV-spike is a promising vaccine candidate for both preventing COVID-19 and enhancing the anti-tumor response. One Sentence Summary A herpes oncolytic viral vector-based vaccine is a promising vaccine with dual roles in preventing COVID-19 and treating tumor progression To test whether OV-spike injection could induce anti-S-specific antibodies, normal BALB/c mice 142 were vaccinated on day 0 with 1×10 6 or 5×10 5 plaque-forming units (pfu) of OV-spike via 143 intravenous (i.v.) administration. Mice were administered 1×10 6 pfu OV-Q1 or saline (mock) as 144 8 negative controls. On day 14, the mice were boosted with a second dose. Serum samples were 145 collected every 7 days for 10 weeks. High levels of anti-S-specific antibodies could be detected as 146 early as day 21 (Fig. 3A) . The production of the antibodies peaked on day 28 and gradually 147 decreased, though a substantial amount still was present on day 70 (Fig. 3B ). One hundred percent 148 of tested mice produced anti-S antibodies on days 21 and 28, and over 50% of the mice still 149 produced substantial levels of the antibodies on day 70 (Fig. 3C) . Meanwhile, mice of a different 150 strain, C57BL/6, were also i.v. injected with 1×10 6 pfu of OV-spike to validate the results. The S1 , B and C). Furthermore, 154 we also vaccinated C57BL/6 mice intraperitoneally (i.p), with 1×10 6 pfu or 2×10 6 pfu OV-spike 155 on days 0 and 14 to test an alternative administration route. Similar results were observed but with 156 a clearer dose-dependent response (Fig. 3 , D to F). Most mice started to produce anti-S-specific 157 antibodies rapidly after day 7, and in general, mice in the high OV-spike dose group produced 158 antibodies more quickly than those in the corresponding low dose group (Fig. 3F ). 160 live SARS-CoV-2 as well as the B.1.1.7 variant 161 We used an enzyme-linked immunosorbent assay (ELISA) to measure the binding affinity of 162 serum samples from vaccinated mice to S protein. Only the sera from OV-spike-immunized mice 163 had a high level of binding affinity with S protein, and the major binding epitope was in S1 subunit 164 with less binding to S2 subunit and nucleocapsid protein (NP) (Fig. 4A ). Flow cytometry further 165 confirmed this result, as the sera from OV-spike-immunized mice could efficiently bind to 166 HEK293T cells expressing S protein on the cell surface (Fig. 4B) . A neutralization assay with the 167 9 VSV-SARS-CoV-2 chimeric virus revealed that sera from OV-spike-immunized mice could 168 neutralize viral infection in a dose-dependent manner ( Fig. 4C and fig. S2, A and B) , and the sera 169 collected from OV-spike immunized mice showed neutralization capacity up to a 320-fold dilution 170 but did not at a 640-fold dilution (Fig. 4, C and D) . To further confirm the neutralization function 171 of sera from OV-spike vaccinated mice, prior to infection of Vero cells, live WT SARS-CoV-2 172 virus was preincubated with the diluted sera from mice immunized with OV-spike or OV-Q1 in a 173 BSL3 lab. The extent of viral infection was determined using an immunoplaque assay. We found 174 that the sera collected from OV-spike-immunized mice significantly reduced live WT SARS-CoV-175 2 infection in a dose-dependent manner compared to sera from OV-Q1-immunized mice (Fig. 4 , 176 E and F). The neutralization capacity of sera from vaccinated mice was also confirmed with a 177 traditional plaque assay ( fig. S2C ). A variant of SARS-CoV-2, named B.1.1.7 and informally known as the "British variant", is rapidly 179 spreading internationally. This strain can render SARS-CoV-2 to escape protection from COVID-180 19 antibodies or existing vaccines (31). Therefore, we also tested whether our OV-spike vaccine 181 could prevent infection by the B.1.1.7 variant. First, we compared the binding affinity of S1 subunit 182 from WT and the B.1.1.7 variant to the sera collected from OV-spike-immunized C57BL/6 and 183 BALB/c mice. The binding affinity was similar for the S1 subunits of the B.1.1.7 variant and WT 184 strain (Fig. 4G) . We also measured the ability of sera from OV-spike vaccinated mice to neutralize to that collected from OV-Q1 groups ( Fig. 4H and fig. S2D ). Furthermore, mice vaccinated with 246 Vaccine safety is a vital concern in clinical application. We thus evaluated the adverse effects of 247 OV-spike vaccine. The same dose of OV-Q1 or OV-spike was injected into tumor-free mice on 248 day 0. We observed that the injection sites had no significant redness and swelling (data not shown). 249 We measured mouse temperature and body weight at the indicated timepoints. Neither fever nor Our current study provides proof-of-concept for dual roles of OV-spike in multiple tumor models. In clinical practice, we anticipate this vaccine could be best suited for local injection into solid 292 tumors, such as melanoma and sarcoma. As the vaccine can specifically infect and be amplified patients, who could likely benefit from enhanced innate and adaptive immunity, given prior work 304 demonstrating improved immunity mediated by OV (28, 29, 43) . 305 An important concern for a vaccine is its safety. Based on the dose and the injection timeline of OV-spike was generated using the fHsvQuik-1 system, as previously described (29, 30) . The full-345 length SARS-CoV-2 S protein was fused with the oHSV glycoprotein D transmembrane domain 346 and intracellular domain. The fusion protein was inserted into pT-oriSIE4/5 following the HSV 347 pIE4/5 promoter to construct pT-oriSIE4/5-spike. pT-oriSIE4/5-spike or pT-oriSIE4/5 was 348 recombined with fHsvQuik-1 for engineering OV-spike and OV-Q1, respectively. Vero cells were 349 used for propagating and titrating the viruses. Virus titration was performed using plaque assays. The B16 melanoma mouse model was established by injecting 5×10 5 B16 cells s.c. 5 days before 441 OV or saline injection into C57BL/6 mice. On day 0 and day 2, 2×10 6 pfu OV-Q1 or OV-spike 442 22 was intratumorally injected and saline was injected as a control. Tumor size was monitored every 443 3 days. Peripheral blood samples were collected once a week after treatment. The mice were 444 euthanized by ketamine/xylazine at 100/10 mg/kg when the tumor volume was over 1500 mm 3 . 445 The MC38 and ID8 colon adenocarcinoma and ovarian cancer mouse models were established by 446 injecting 5×10 5 MC38 cells or 1×10 6 ID8 cells i.p. 4 days before OV or saline injection into 447 C57BL/6 mice. On day 0, 2×10 6 pfu OV-Q1 or OV-spike were i.p. injected and saline was injected Mice organs including lung, brain, kidney, and liver were freshly isolated from 1×10 6 pfu OV- a Student's t test was used to compare the 2 independent groups. One-way ANOVA models or 489 generalized linear models were used to compare 3 or more independent groups. For data with 490 repeated measures from the same subject, linear mixed models were used to account for the 491 variance and covariance structure due to repeated measures. Survival functions were estimated by 492 the Kaplan-Meier method and compared by the two-sided log-rank test. All tests were two-sided. patients without cancer (n = 11) or with cancer (n = 13) was detected by ELISA using SARS-CoV-692 Getting oncolytic virus therapies off the ground Recent advances of oncolytic virus in cancer therapy Oncolytic virus 550 immunotherapy: future prospects for oncology Oncolytic herpes simplex virus vectors for cancer virotherapy Talimogene laherparepvec (T-VEC) for the treatment 554 of advanced melanoma Oncolytic herpes simplex virus-based strategies: toward a breakthrough 557 in glioblastoma therapy Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Oncolytic herpes simplex virus interactions with the host 565 immune system Modulation of the Intratumoral Immune Landscape 567 by Oncolytic Herpes Simplex Virus Virotherapy Herpes simplex virus as an in situ cancer 569 vaccine for the induction of specific anti-tumor immunity Cholesterol 25-hydroxylase suppresses SARS-CoV-574 2 replication by blocking membrane fusion Analyses of Risk, Racial Disparity, and Outcomes Among US 577 Patients With Cancer and COVID-19 Infection Next-generation vaccine platforms for COVID-19 NK cells impede glioblastoma virotherapy through 583 NKp30 and NKp46 natural cytotoxicity receptors Glioblastoma Virotherapy by Inhibiting the Innate Immune Response An oncolytic herpesvirus expressing E-cadherin 590 improves survival in mouse models of glioblastoma Development of a rapid 592 method to generate multiple oncolytic HSV vectors and their in vivo evaluation using 593 syngeneic mouse tumor models Neutralization of SARS-CoV-2 lineage B.1.1.7 596 pseudovirus by BNT162b2 vaccine-elicited human sera A Review of the Progress and Challenges of 598 Developing a Vaccine for COVID-19 SARS-CoV-2 immunity: review and 600 applications to phase 3 vaccine candidates COVID-19: A review of therapeutic strategies and 602 vaccine candidates Immunosuppressive networks in the tumour environment and their therapeutic 604 relevance A single-dose live-attenuated 613 YF17D-vectored SARS-CoV-2 vaccine candidate Development of a multi-617 antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform Single-shot Ad26 629 vaccine protects against SARS-CoV-2 in rhesus macaques Phase I/II study of COVID-19 RNA vaccine BNT162b1 634 in adults Safety, tolerability, and immunogenicity of a recombinant 638 adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-639 randomised, first-in-human trial Immune-mediated approaches against COVID-19 Lymphopenia during the COVID-19 infection: What it shows and what can be learned The histone 647 deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected 648 glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma 649 interferon Talimogene Laherparepvec Other Oncolytic Viruses for the Treatment of Melanoma Early transmissibility assessment 654 of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom Neutralization of SARS-CoV-2 lineage B.1.1.7 658 pseudovirus by BNT162b2 vaccine-elicited human sera Stenoparib, an Inhibitor of Cellular Poly Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human 663 Growth, detection, 665 quantification, and inactivation of SARS-CoV-2 Acknowledgements: The authors thank Sean P.J. Whelan for sharing the VSV-SARS-CoV-2 669 virus. We also thank Veronica Karpinski for her technical support on ELISpot assay The California Institute for conceived, designed, and supervised 676 the project Feng designed and/or conducted 678 experiments. Y. Sun, L. Tian, J. Zhang performed data analyses Caligiuri wrote, reviewed and/or revised the paper. All authors discussed the results and 680 commented on the manuscript Competing interests: The authors have no direct conflict of interest to declare Data and materials availability: All data associated with this study are present in the paper or 683 the Supplementary Figures B) The ability of serum samples from SARS-CoV-2-infected people with cancer = 13) or without cancer (n = 11) to neutralize VSV-SARS-CoV-2 infection in vitro. (C) The ability 694 of serum samples from SARS-CoV-2-infected people with or without cancer to neutralize the live 695 Representative images of the 696 neutralization assay against live SARS-CoV-2 infection of serum samples from COVID-19 697 patients with or without cancer. Error bars represent standard deviations of triplicates Engineering and validation of OV-spike. (A) Schematic map of the oncolytic viruses 705 used in this study. Top: genetic map of wild-type HSV-1. Middle: genetic map of the control oHSV 706 (OV-Q1) with deletion of 2 copies of γ34.5, dysfunctional ICP6, and insertion of the GFP gene Bottom: genetic map of OV-spike showing the inserted S protein-coding gene fused with 708 glycoprotein D (S-gD). (B) The construction model for OV-spike. The blue dots represent S 709 protein fused with the transmembrane and intracellular domain of gD, and the red rhombus shows 710 wild-type gD. (C) Transmission electron micrographs of control OV-Q1 D) Immunogold labeling using antibodies against the SARS-CoV-2 S 712 protein for OV-Q1 (left panel) compared to OV-spike CoV-2 S protein in control OV-Q1 and OV-spike virus particles as determined by immunoblotting 714 assay. (F) Expression of the SARS-CoV-2 S protein mRNA in OV-Q1-and OV-spike Expression of the SARS-CoV-2 S 716 protein in OV-Q1-and OV-spike-infected Vero cells as detected by flow cytometry. Error bars 717 represent standard deviations of triplicates A-C) BALB/c 734 mice were vaccinated on days 0 and 14 with 1×10 6 plaque-forming units (pfu) or 5×10 5 pfu of OV-735 spike by intravenous (i.v.) administration and 1×10 6 pfu of OV-Q1 or saline (mock) as a negative A) Anti-S protein antibody levels of sera on days 0, 21, 42, and 63, as assessed by an S 737 protein-specific enzyme-linked immunosorbent assay (ELISA). (B) Overview of serum anti-S 738 protein antibody levels from days 0 to 70. (C) Anti-S antibody production rates in vaccinated mice 739 at the indicated days (D) Serum anti-S protein antibody 741 levels on days 0, 21, 28, 35, 42, and 49, as assessed by an S protein-specific ELISA. (E) Overview 742 of serum anti-S protein antibody levels from days 0 to 49. (F) Anti-S antibody production rates in 743 vaccinated mice at the indicated days. Data in (A) and (D) are shown in mean value, and statistical 744 analyses were performed by one-way ANOVA with P values corrected for multiple comparisons 745 by Bonferroni method multiple comparisons test (n = 3-5 mice for mock group and OV-Q1 group Sera from OV-spike vaccinated mice inhibits both VSV-SARS-CoV-2 and SARS CoV-2 infection in vitro. (A) ELISA-based binding assessment for S protein or S protein subunit 760 1 (S1) and sera from mice vaccinated with saline (mock), OV-Q1 or OV-spike. (B) The left panel OV-Q1 or OV-spike and S protein expressed on 293T cells. The data are summarized in the right 763 panel. (C) VSV-SARS-CoV-2 neutralization by sera from mice vaccinated with saline (mock OV-Q1 or OV-spike at the indicated dilutions. (D) The neutralization titer of the sera from 765 vaccinated mice. (E) The neutralization against live SARS-CoV-2 virus of the sera from 766 vaccinated mice. (F) The image data of the neutralization assay against live SARS-CoV-2 virus OV-Q1, and OV-spike-vaccinated mice was measured by ELISA. (H) The 769 neutralization against live B.1.1.7 mutant strain infection of the sera from vaccinated mice. (I) The 770 neutralization titer against wild-type strain SARS-CoV-2 (WT) and B.1.1.7 variant of the sera from 771 vaccinated mice. Error bars represent standard deviations of triplicates. Statistical analyses were 772 performed by one-way ANOVA with P values corrected for multiple comparisons by Bonferroni 773 method multiple comparisons test A and B) A mouse melanoma tumor model was established 785 by s.c. injection of 5×10 5 B16 cells. On day 0 and day 2, the mice were intratumorally injected of OV-Q1 or OV-spike. (A) Melanoma tumor volume in mice 787 with the indicated treatments. (B) ELISA-based assessment of anti-S protein antibody levels in the 788 sera from these mice at the indicated times. (C and D) A colon tumor mouse model was established 789 by i.p. injection of 5×10 5 MC38 cells ELISA-based assessment of anti-S protein antibody levels in the sera from these mice at the 792 indicated times. (E and F) A mouse ovarian tumor model was established by i.p. injection of 1×10 6 793 ID8 cells E) The tumor volume of mice with the indicated treatments. (F) ELISA-795 based assessment of anti-S protein antibody levels in the sera from these mice at the indicated 796 times. (G and H) The neutralization against live wild-type SARS-CoV-2 strain The 798 neutralization titer against live wild-type strain (WT) and B.1.1.7 variant infection of the sera from 799 vaccinated mice bearing tumors. Error bars represent standard deviations. Data in B, D, and F are 800 shown in mean value. Statistical analyses were performed by one-way ANOVA with P values 801 corrected for multiple comparisons by Bonferroni method multiple comparisons test for Two-sample t test with two-tail distribution was applied for (G), (H) 803 and (I)